Sugi Predict

Sugi Predict / Targets / POR

POR

NADPH--cytochrome P450 reductase · P16435 · POR on Sugi Atlas →

1,088 patent compounds predicted against POR, 486 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL28845339 SCHEMBL28845339 1.00 7/20
SCHEMBL24119167 SCHEMBL24119167 0.68 7/20
SCHEMBL10422153 SCHEMBL10422153 0.43 7/20
SCHEMBL5940235 SCHEMBL5940235 1.00 6/20
SCHEMBL5940497 SCHEMBL5940497 1.00 6/20
SCHEMBL8189008 SCHEMBL8189008 0.75 6/20
SCHEMBL24119166 SCHEMBL24119166 0.72 6/20
SCHEMBL5940262 SCHEMBL5940262 0.68 6/20
SCHEMBL17468347 SCHEMBL17468347 0.38 6/20
SCHEMBL10459823 SCHEMBL10459823 0.59 5/20
SCHEMBL9751019 SCHEMBL9751019 0.54 5/20
SCHEMBL25649954 SCHEMBL25649954 0.52 5/20
SCHEMBL23482222 SCHEMBL23482222 0.50 5/20
SCHEMBL24119165 SCHEMBL24119165 0.44 5/20
SCHEMBL5940435 SCHEMBL5940435 0.71 4/20
SCHEMBL5940394 SCHEMBL5940394 0.68 4/20
(3R)-Dunnione (3R)-Dunnione (SCHEMBL103115) 0.63 4/20
(3R)-Dunnione (3R)-Dunnione (SCHEMBL29468606) 0.63 4/20
(3R)-Dunnione (3R)-Dunnione (SCHEMBL6052903) 0.56 4/20
Alpha-Dunnione Alpha-Dunnione (SCHEMBL940069) 0.56 4/20

Clinical trials — most relevant to POR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Platelet Inhibition in Patients With Systolic Heart Failure PHASE4COMPLETED
Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy PHASE4UNKNOWN
Tamoxifen Citrate in Patients With Breast Cancer PHASE3UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). PHASE2UNKNOWN
Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56 PHASE2COMPLETED
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) PHASE2COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer PHASE1COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems PHASE1COMPLETED
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215 PHASE1COMPLETED
A Study to Evaluate the Effect of Genotype on LY2216684 PHASE1COMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897 nanCOMPLETED
Cyclophosphamide in Lupus Nephritis nanUNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Optimisation of Nutrition and Medication for Acutely Admitted Older Medical Patients nanUNKNOWN
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency nanCOMPLETED
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases nanCOMPLETED
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke nanCOMPLETED
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial) nanCOMPLETED
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a POR binder may also engage these)

ProteinNameSimilarity
Q3SYT8 — 1.000 Q3SYT8 →
P37040 — 1.000 P37040 →
Q27597 — 0.999 Q27597 →
Q07994 — 0.999 Q07994 →
P04175 — 0.999 P04175 →
P37039 — 0.999 P37039 →
P00388 — 0.997 P00388 →
P00389 — 0.996 P00389 →
P19618 — 0.994 P19618 →
Q9SUM3 — 0.993 Q9SUM3 →
P37116 — 0.992 P37116 →
Q55CT1 — 0.990 Q55CT1 →
Q0CY37 — 0.990 Q0CY37 →
Q9SB48 — 0.989 Q9SB48 →
Q1DWN4 — 0.989 Q1DWN4 →
Q0P487 — 0.988 Q0P487 →
A0A7T9QPQ1 — 0.988 A0A7T9QPQ1 →
Q653S9 — 0.988 Q653S9 →
O74557 — 0.988 O74557 →
A2QCV4 — 0.987 A2QCV4 →
Q8Z458 — 0.987 Q8Z458 →
A0A2U1KZS6 — 0.987 A0A2U1KZS6 →
Q05001 — 0.986 Q05001 →
A0A2U1LIM9 — 0.985 A0A2U1LIM9 →
P17571 — 0.985 P17571 →
P37201 — 0.985 P37201 →
P36587 — 0.985 P36587 →
Q9HDG2 — 0.985 Q9HDG2 →
C5YJG8 — 0.984 C5YJG8 →
A5E7U2 — 0.984 A5E7U2 →